# Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.

> **NCT00334295** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 35 (actual)

## Conditions studied

- Endometrial Carcinoma

## Interventions

- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT00334295
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2012-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00334295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00334295, "Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00334295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*